UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2021 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-33957 ___________________________ HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Its Charter) (State or other jurisdiction o ...

Harvard Bioscience, Inc. (NASDAQ:HBIO) Q4 2021 Earnings Conference Call March 8, 2022 8:00 AM ET Company Participants David Sirois - Director of Corporate Accounting & SEC Reporting James Green - President & Chief Executive Officer Michael Rossi - Chief Financial Officer Conference Call Participants Paul Knight - KeyBanc Tim Chiang - Northland Securities Lisa Springer - Singular Research Bruce Jackson - Benchmark Operator Good morning and thank you for standing by. Welcome to the Fourth Quarter 2021 Harvard ...

NASDAQ: HBIO Q4'21 Earnings Presentation Jim Green, Chairman, President & CEO Mike Rossi, CFO March 8, 2022 Forward-Looking Statements and Non-GAAP Financial Information Forward-Looking Statements Information in this presentation or in oral statements of the management of the Company may include forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. You can identify these statements by our use of such words as "will," "gu ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2021 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from_____to _____ Commission file number 001-33957 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Its Charter) (State or other jurisdiction of (I.R.S. Empl ...

NASDAQ: HBIO Q3'21 Earnings Presentation Jim Green, Chairman, President & CEO Mike Rossi, CFO November 3, 2021 Forward-Looking Statements and Non-GAAP Financial Information Forward-Looking Statements Information in this presentation or in oral statements of the management of the Company may include forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. You can identify these statements by our use of such words as "will," ...

Harvard Bioscience, Inc. (NASDAQ:HBIO) Q3 2021 Earnings Conference Call November 3, 2021 8:00 AM ET Company Participants David Sirois - Director, Corporate Accounting & SEC Reporting James Green - President, CEO & Chairman Michael Rossi - CFO Conference Call Participants Lisa Springer - Singular Research Paul Knight - KeyBanc Capital Markets Timothy Chiang - Northland Capital Markets Bruce Jackson - The Benchmark Company Ailon Grushkin - Nano-Cap Growth Operator Good day, and thank you for standing by. Welc ...

NASDAQ: HBIO Q2'21 Earnings Presentation Jim Green, Chairman, President & CEO Mike Rossi, CFO August 5, 2021 Forward-Looking Statements and Non-GAAP Financial Information Forward-Looking Statements Information in this presentation or in oral statements of the management of the Company may include forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. You can identify these statements by our use of such words as "will," "g ...

Harvard Bioscience, Inc. (NASDAQ:HBIO) Q2 2021 Earnings Conference Call August 5, 2021 8:00 AM ET Company Participants David Sirois - Director, Corporate Accounting & SEC Reporting James Green - Chairman, President and CEO Michael Rossi - CFO Conference Call Participants Paul Knight - KeyBanc Timothy Chiang - Northland Capital Lisa Springer - Singular Research Bruce Jackson - The Benchmark Company Operator Good day, and thank you for standing by. Welcome to the Q2 2021 Harvard Bioscience Conference Call. [O ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2021 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from _____ to _____ Commission file number 001-33957 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 04-3306140 (State or other jurisdictio ...

Harvard Bioscience, Inc. (NASDAQ:HBIO) Q1 2021 Earnings Conference Call May 6, 2021 8:00 AM ET Company Participants David Sirois - Director, Corporate Accounting & SEC Reporting James Green - President, CEO & Chairman Michael Rossi - CFO Conference Call Participants Paul Knight - KeyBanc Capital Markets Timothy Chiang - Northland Capital Markets Lisa Springer - Singular Research Bruce Jackson - The Benchmark Company Operator Good day and thank you for standing by and welcome to the Q1 2021 Harvard Bioscienc ...